Cookie Img

Tenvir-EM Emtricitabine and Tenofovir Disoproxil Fumarate

Tenvir-EM Emtricitabine and Tenofovir Disoproxil Fumarate
Tenvir-EM Emtricitabine and Tenofovir Disoproxil Fumarate
Product Code : 01
2000 INR
Price And Quantity
Minimum Order Quantity :
1
Unit of Measure :
Box/Boxes
Price :
2000 INR
Product Specifications
Drug Type :
Generic Drugs
Ingredients :
Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg
Physical Form :
Tablets
Function :
Anti HIV
Recommended For :
HIV positive patients
Dosage :
Emtricitabine 200mg and Tenofovir Disoproxil Fumarate 300mg
Dosage Guidelines :
As guided by physician
Storage Instructions :
Room Temperature (25 C Temperature)
Product Description
TENMAC-EM

Each tablet contains:
  • Tenofovir Disoproxil Fumarate 300 mg
  • Emtricitabine 200mg

CONTRAINDICATIONS:

Do not use TENMAC-EM for pre-exposure prophylaxis in individuals with unknown or positive HIV-1 status. TENMAC-EM should be used in HIV-infected patients only in combination with other anti-retroviral agents.

SIDE EFFECTS:

In HIV1 infected patients, the most common adverse reactions (incidence greater than or equal to 10%) are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. In HIV-1 uninfected individuals in PrEP trials, adverse reactions that were reported by more than 2% of TENMAC-EM subjects and more frequently than by placebo subjects were headache, abdominal pain and weight decreased.

PACKING:

HDPE Bottle packs of 30 tablets and packed in a unit carton along with package insert.

SHELF LIFE AND STORAGE:

24 months from the date of manufacturing, below 30°C.
TENMAC-EM

Each tablet contains:
  • Tenofovir Disoproxil Fumarate 300 mg
  • Emtricitabine 200mg

CONTRAINDICATIONS:

Do not use TENMAC-EM for pre-exposure prophylaxis in individuals with unknown or positive HIV-1 status. TENMAC-EM should be used in HIV-infected patients only in combination with other anti-retroviral agents.

SIDE EFFECTS:

In HIV1 infected patients, the most common adverse reactions (incidence greater than or equal to 10%) are diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, and rash. In HIV-1 uninfected individuals in PrEP trials, adverse reactions that were reported by more than 2% of TENMAC-EM subjects and more frequently than by placebo subjects were headache, abdominal pain and weight decreased.

PACKING:

HDPE Bottle packs of 30 tablets and packed in a unit carton along with package insert.

SHELF LIFE AND STORAGE:

24 months from the date of manufacturing, below 30°C.
Contact Us

507-508, 5th Floor, The Emporio by Kunj, Opposite 4D Square Mall, Near Vishwakarma Engineering College, Visat-Gandhinagar Highway, Chandkheda, Ahmedabad, Gujarat, 382424, India
Phone :+919901290067